Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study
{{output}}
Background: Radium-223 (223Ra) therapy has been available since 2013 for metastatic castrate-resistant prostate cancer (mCRPC). However, only in 2017 223Ra was approved by the National Health Surveillance Agency in Brazil. We aim... ...
